Effects of combined treatment with eldecalcitol and alendronate on bone mass, mechanical properties, and bone histomorphometry in ovariectomized rats: A comparison with alfacalcidol and alendronate

Bone

Volumn 52, Issue 1, 2013, Pages 181-188

  Sugimoto, Masanori ^a   Futaki, Nobuko ^b   Harada, Masahiro ^b   Kaku, Shinsuke ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

^b Taisho Toyama Pharmaceutical Co Ltd   (Japan)

Author keywords

Additive effect; Alendronate; Alfacalcidol; Combination therapy; ELD; Eldecalcitol

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; ELDECALCITOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE MASS; BONE STRENGTH; BONE STRUCTURE; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; FEMUR; LUMBAR SPINE; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; RAT;

ALENDRONATE; ANIMALS; BIOMECHANICS; BONE AND BONES; BONE DENSITY; DRUG THERAPY, COMBINATION; FEMALE; HYDROXYCHOLECALCIFEROLS; OVARIECTOMY; RATS; RATS, WISTAR; VITAMIN D;

EID: 84867622282     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.09.031     Document Type: Article

References (32)

1. Kanis J.A. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994, 4:368-381.
2. Egermann M., Goldhahn J., Schneider E. Animal models for fracture treatment in osteoporosis. Osteoporos Int 2005, 16:129-138.
3. Moniz C., Dew T., Dixon T. Prevalence of vitamin D inadequacy in osteoporotic hip fracture patients in London. Curr Med Res Opin 2005, 21:1891-1894.
4. Nurmi I., Kaukonen J.P., Luthje P., Naboulsi H., Tanninen S., Kataja M., et al. Half of the patients with an acute hip fracture suffer from hypovitaminosis D: a prospective study in southeastern Finland. Osteoporos Int 2005, 16:2018-2024.
5. Akiba T., Marumo F., Owada A., Kurihara S., Inoue A., Chida Y., et al. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1998, 32:238-246.
6. Papadimitropoulos E., Wells G., Shea B., Gillespie W., Weaver B., Zytaruk N., et al. Meta-analyses of therapies for postmenopausal osteoporosis. VIII: meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 2002, 23:560-569.
7. Erbe R.G., Bromm S., Stangassinger M. Short-term prophylaxis against estrogen depletion-induced bone loss with calcitriol does not provide long-term beneficial effects on cancellous bone mass or structure in ovariectomized rats. Osteoporos Int 1998, 8:82-91.
8. Erben R.G., Weise H., Sinowatz F., Rambeck W.A., Zucke H. Vitamin D metabolites prevent vertebral osteopenia in ovariectomized rats. Calcif Tissue Int 1992, 50:228-236.
9. Shiraishi A., Takeda S., Masaki T., Higuchi Y., Uchiyama Y., Kubodera N., et al. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res 2000, 15:770-779.
10. Sjöden G., Smith C., Lindgren U., DeLuca H.F. 1 alpha-Hydroxyvitamin D2 is less toxic than 1 alpha-hydroxyvitamin D3 in the rat. Proc Soc Exp Biol Med 1985, 178:432-436.
11. Erben R.G., Scutt A.M., Miao D., Kollenkirchen U., Haberey M. Short-term treatment of rats with high dose 1,25-dihydroxyvitamin D3 stimulates bone formation and increases the number of osteoblast precursor cells in bone marrow. Endocrinology 1997, 138:4629-4635.
12. Erben R.G., Bromm S., Stangassinger M. Therapeutic efficacy of 1α,25-dihydroxyvitamin D3 and calcium in osteopenic ovariectomized rats: evidence for a direct anabolic effect of 1α,25-dihydroxyvitamin D3 on bone. Endocrinology 1998, 139:4319-4328.
13. Uchiyama Y., Higuchi Y., Takeda S., Masaki T., Shira-ishi A., Sato K., et al. ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone 2002, 30:582-588.
14. Ono Y., Kawase A., Watanabe H., Shiraishi A., Takeda S., Higuchi Y., et al. Syntheses and preventive effects of analogues related to alpha,25-dihydroxy-2beta-(3-hydroxypropoxy) vitamin D3 (ED-71) on bone mineral loss in ovariectomized rats. Bioorg Med Chem 1998, 6:2517-2523.
15. Matsumoto T., Miki T., Hagino H., Sugimoto T., Okamoto S., Hirota T., et al. A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 2005, 90:5031-5036.
16. 3 analog, eldecalcitol, prevents the risk of osteoporotic fractures - a randomized, active comparator, double-blind study. Bone 2011, 49:605-612.
17. Colucci S., Minielli V., Zambonin G., Cirulli N., Mori G., Serra M., et al. Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces. Calcif Tissue Int 1998, 63:230-235.
18. Azuma Y., Sato H., Oue Y., Okabe K., Ohta T., Tsuchimoto M., et al. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 1995, 16:235-245.
19. Liberman U.A., Weiss S.R., Bröll J., Minne H.W., Quan H., Bell N.H., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995, 333:1437-1443.
20. Black D.M., Thompson D.E., Bauer D.C., Ensrud K., Musliner T., Hochberg M.C., et al. Fracture Intervention Trial. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000, 85:4118-4124.
21. Azuma Y., Oue Y., Kanatani H., Ohta T., Kiyoki M., Komoriya K. Effects of continuous alendronate treatment on bone mass and mechanical properties in ovariectomized rats: comparison with pamidronate and etidronate in growing rats. J Pharmacol Exp Ther 1998, 286:128-135.
22. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998, 19:80-100.
23. Sakai S., Endo K., Takeda S., Mihara M., Shiraishi A. Combination therapy with alendronate and eldecalcitol has therapeutic advantages over monotherapy by improving bone strength. Bone 2012, 50:1054-1063.
24. Mosekilde L., Danielsen C.C., Knudsen U.B. The effects of aging and ovariectomy on the vertebral bone mass and biomechanical properties of mature rats. Bone 1993, 14:1-6.
25. Katsumata T., Nakamura T., Ohnishi H., Sakurama T. Intermittent cyclical etidronate treatment maintains the mass, structure and the mechanical property of bone in ovariectomized rats. J Bone Miner Res 1995, 10:921-931.
26. Green J.R., Müller K., Jaeggi K.A. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994, 9:745-752.
27. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987, 2:595-610.
28. de Freitas P.H., Hasegawa T., Takeda S., Sasaki M., Tabata C., Oda K., et al. Eldecalcitol, a second-generation vitamin D analog, drives bone minimodeling and reduces osteoclastic number in trabecular bone of ovariectomized rats. Bone 2011, 49:335-342.
29. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., Meunier P.J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997, 100:1475-1480.
30. Chapuy M.C., Arlot M.E., Duboeuf F., Brun J., Crouzet B., Arnaud S., et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992, 327:1637-1642.
31. Turner C.H. Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 2002, 13:97-104.
32. Saito M., Mori S., Mashiba T., Komatsubara S., Marumo K. Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs. Osteoporos Int 2008, 19:1343-1354.